Literature DB >> 17517903

High-content imaging analysis of the knockdown effects of validated siRNAs and antisense oligonucleotides.

Jonathan Low1, Michele Dowless, Wayne Blosser, Thomas Vincent, Scott Davis, Jeff Hodson, Erich Koller, Eric Marcusson, Kerry Blanchard, Louis Stancato.   

Abstract

High-content imaging (HCI) provides researchers with a powerful tool for understanding cellular processes. Although phenotypic analysis generated through HCI is a potent technique to determine the overall cellular effects of a given treatment, it frequently produces complex data sets requiring extensive interpretation. The authors developed statistical analyses to decrease the time spent to determine the outcome of each HCI assay and to better understand complex phenotypic changes. To test these tools, the authors performed a comparison experiment between 2 types of oligonucleotide-mediated gene silencing (OMGS), antisense oligonucleotides (ASOs), and short, double-stranded RNAs (siRNAs). Although similar in chemical structure, these 2 methods differ in cellular mechanism of action and off-target effects. Using a library of 50 validated ASOs and siRNAs to the same targets, the authors characterized the differential effects of these 2 technologies using a HeLa cell G2-M cell cycle assay. Although knockdown of a variety of targets by ASOs or siRNAs affected the cell cycle profile, few of those targets were affected by both ASOs and siRNAs. Distribution analysis of population changes induced through target knockdown led to the identification of targets that, when inhibited, could affect the G2-M transition in the cell cycle in a statistically significant manner. The distinctly different mechanisms of action of these 2 forms of gene silencing may help define the use of these treatments in both clinical and research environments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17517903     DOI: 10.1177/1087057107302675

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  7 in total

1.  A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells.

Authors:  C M Tate; R Pallini; L Ricci-Vitiani; M Dowless; T Shiyanova; G Q D'Alessandris; L Morgante; S Giannetti; L M Larocca; S di Martino; S W Rowlinson; R De Maria; L Stancato
Journal:  Cell Death Differ       Date:  2012-04-27       Impact factor: 15.828

2.  Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.

Authors:  Caitlin D Lowery; Michele Dowless; Matthew Renschler; Wayne Blosser; Alle B VanWye; Jennifer R Stephens; Philip W Iversen; Aimee Bence Lin; Richard P Beckmann; Kateryna Krytska; Kristina A Cole; John M Maris; Douglas S Hawkins; Brian P Rubin; Raushan T Kurmasheva; Peter J Houghton; Richard Gorlick; E Anders Kolb; Min H Kang; C Patrick Reynolds; Stephen W Erickson; Beverly A Teicher; Malcolm A Smith; Louis F Stancato
Journal:  Clin Cancer Res       Date:  2018-12-18       Impact factor: 12.531

3.  Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.

Authors:  Constance King; Henry Diaz; Darlene Barnard; David Barda; David Clawson; Wayne Blosser; Karen Cox; Sherry Guo; Mark Marshall
Journal:  Invest New Drugs       Date:  2013-10-10       Impact factor: 3.850

4.  Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.

Authors:  Michele Dowless; Caitlin D Lowery; Terry Shackleford; Matthew Renschler; Jennifer Stephens; Robert Flack; Wayne Blosser; Simone Gupta; Julie Stewart; Yue Webster; Jack Dempsey; Alle B VanWye; Philip Ebert; Philip Iversen; Jonathan B Olsen; Xueqian Gong; Sean Buchanan; Peter Houghton; Louis Stancato
Journal:  Clin Cancer Res       Date:  2018-08-21       Impact factor: 12.531

5.  LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.

Authors:  Darlene Barnard; H Bruce Diaz; Teresa Burke; Gregory Donoho; Richard Beckmann; Bonita Jones; David Barda; Constance King; Mark Marshall
Journal:  Invest New Drugs       Date:  2015-11-27       Impact factor: 3.850

6.  Phenotypic fingerprinting of small molecule cell cycle kinase inhibitors for drug discovery.

Authors:  Jonathan Low; Arunava Chakravartty; Wayne Blosser; Michele Dowless; Christopher Chalfant; Patty Bragger; Louis Stancato
Journal:  Curr Chem Genomics       Date:  2009-03-24

Review 7.  Applications of high content screening in life science research.

Authors:  Joseph M Zock
Journal:  Comb Chem High Throughput Screen       Date:  2009-11       Impact factor: 1.339

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.